Trevi Therapeutics, Inc. Common Stock
TRVITrevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for underserved populations with rare or chronic conditions. The company’s lead product candidate, Haduvio (nalbuphine ER), is designed to treat persistent cough and other respiratory disorders. Trevi aims to leverage its proprietary formulations and delivery technologies to address unmet medical needs in neurology and respiratory health.
Company News
Trevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before underwriting costs. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis and other lung conditi...
Trevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before fees. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF, non-IPF ILD, and refractory chronic cough patients. The offering is expect...
The chronic refractory cough market is projected to expand by 2034, driven by rising patient diagnoses, improved awareness, and emerging therapies targeting refractory cough conditions.
Law firm Kaskela Law LLC is investigating Trevi Therapeutics for potential securities law violations or breaches of fiduciary duties, encouraging long-term investors to contact them for more information.
The pulmonary fibrosis market is driven by the increasing prevalence of the disease, especially idiopathic pulmonary fibrosis, among the aging population. Innovations in drug development and diagnostics, favorable reimbursement policies, and greater awareness are fueling market growth. The pipeline appears robust with over 110 active players work...
